MedPath

Tralokinumab Demonstrates Efficacy in Reducing Genital Atopic Dermatitis Severity

• The TRACE study revealed that tralokinumab significantly reduced the severity of genital atopic dermatitis (AD) within three months. • Patients treated with tralokinumab experienced notable improvements in their overall quality of life, as indicated by the TRACE study. • Delgocitinib cream presents a safe therapeutic option for chronic hand eczema due to its low systemic exposure, according to recent findings.

Tralokinumab has shown promise in reducing the severity of genital atopic dermatitis (AD) and improving the quality of life for affected individuals within three months of treatment, according to the TRACE study. The findings, presented at Elevate-Derm West 2024, highlight a potential new approach to managing this challenging condition.

Impact of Tralokinumab on Genital AD

The TRACE study evaluated the efficacy of tralokinumab in patients with genital AD. Results indicated a significant reduction in the severity of AD symptoms in the genital area. This improvement was accompanied by a notable enhancement in the patients' overall quality of life, suggesting that tralokinumab not only addresses the physical symptoms but also the broader impact of the condition.

Delgocitinib Cream for Chronic Hand Eczema

In other research presented at the conference, delgocitinib cream was highlighted as a safe option for treating chronic hand eczema. A poster presentation indicated that the cream offers low systemic exposure, potentially reducing the risk of systemic side effects typically associated with eczema treatments. This makes it a valuable option for patients requiring long-term management of their condition.

Additional Insights from Elevate-Derm West 2024

Elevate-Derm West 2024 also featured discussions on affordable at-home treatments, including microneedling and benzoyl peroxide, as highlighted by Chilukuri. Furthermore, two new sunscreen ingredients, physalis angulata and pycnogenol, were presented as potential agents for preventing heat-induced pigmentation, offering new options for patients concerned about this issue. A study also demonstrated significant reductions in inflammatory and non-inflammatory lesions for Hispanic patients using CAB gel.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Lebrikizumab Shows Promise for Long-Term Management of Atopic Dermatitis in Phase 3 Trial

Phase 3 trial data demonstrates lebrikizumab's efficacy in managing atopic dermatitis (AD) symptoms over 52 weeks, a significant improvement over the 16-week maintenance shown in previous trials.
Lebrikizumab, a monoclonal antibody inhibiting IL-13, shows potential for reducing skin inflammation and itch, key symptoms of AD, with infrequent dosing options.

Delgocitinib Cream Shows Favorable Safety Profile in DELTA 2 Trial for Chronic Hand Eczema

The DELTA 2 trial evaluated the safety and systemic absorption of delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE).
Results showed minimal systemic absorption of delgocitinib with mean plasma concentrations remaining low throughout the 16-week study.

Dermatology Advances: Approvals, Trial Results, and New Guidelines Emerge

The FDA approved bimekizumab for moderate-to-severe hidradenitis suppurativa, marking the first treatment targeting both IL-17A and IL-17F cytokines.
Subcutaneous nivolumab's PDUFA date was updated, based on Phase 3 data demonstrating noninferiority to intravenous nivolumab in renal cell carcinoma.

Lilly's EBGLYSS Demonstrates Efficacy in Atopic Dermatitis Patients Unresponsive to Dupilumab

Eli Lilly's EBGLYSS demonstrated significant improvements in skin condition and itch relief in moderate-to-severe atopic dermatitis patients who had an inadequate response to dupilumab.
In the Phase IIIb ADapt study, 57% of patients achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) score by week 16, increasing to 60% by week 24.

Fall Clinical 2024 Highlights Advances in Acne, Psoriasis, Atopic Dermatitis, and Aesthetic Dermatology

A recent meta-analysis presented at Fall Clinical 2024 indicates comparable efficacy in treating acne vulgaris, offering clinicians more options.
Deucravacitinib has demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as highlighted in the PSORIATYK SCALP trial.

Lebrikizumab Shows Promise in Atopic Dermatitis, Including After Dupilumab Discontinuation

Lebrikizumab (Ebglyss) is FDA-approved for moderate to severe atopic dermatitis in adults and children 12 years and older who haven't responded to topical treatments.
Clinical trials (ADvocate 1, ADvocate 2, and ADhere) demonstrated significant skin clearance and itch relief with lebrikizumab compared to placebo.

Fall Clinical 2024: Leqselvi Shows Promise in Alopecia Areata, Ebglyss Demonstrates Efficacy in Eczema

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, demonstrating significant scalp hair regrowth in patients with severe alopecia areata.
Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of atopic dermatitis patients, showcasing a strong efficacy and safety profile.

Lebrikizumab Shows Promise in Atopic Dermatitis Patients Previously Treated with Dupilumab

Phase 3b ADapt study reveals lebrikizumab significantly improved skin condition and reduced itch in moderate-to-severe atopic dermatitis patients who discontinued dupilumab.
57% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at week 16, increasing to 60% by week 24 with lebrikizumab treatment.

Tralokinumab Demonstrates Sustained Improvement in Atopic Dermatitis Symptoms in Real-World Study

Interim results from the TRACE study show that tralokinumab treatment for nine months significantly improves itch, sleep quality, and overall quality of life in adults with atopic dermatitis.
Improvements were observed in both dupilumab-naive patients and those with prior dupilumab exposure, indicating consistent efficacy across different treatment histories.

Dermatology News Roundup: Bimzelx Expansion, Zoryve sNDA, and HS Insights

Bimzelx gains FDA approval for active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, marking it as the first IL-17A/F inhibitor for four immune-mediated diseases.
Arcutis' Zoryve foam sNDA accepted by the FDA for scalp and body psoriasis, supported by phase 2b and 3 data showing symptom improvement and safety, with a target action date set for May 2025.

Reference News

[1]
Day 3 Recap: Elevate-Derm West 2024 - Dermatology Times
dermatologytimes.com · Nov 10, 2024

TRACE study: tralokinumab reduces genital AD severity & improves QoL within 3 months. Affordable at-home treatments like...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy